Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

UMIN Clinical Trials Registry UMIN000010758.

Who Took Part

According to the abstract, 2 adults were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

The adults were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the adults and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

Double blinded, multicentre, randomised, placebo controlled trial.

Three hospitals in Japan, between June 2013 and August 2019.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Glucose Intolerance, Japan, Prediabetic State and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 2 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 13 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (BMJ (Clinical research ed.)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.